Therapie
-
Since 2002, the Leem (French Association of Pharmaceutical Companies) has conducted a survey every two years to update the attractiveness of France for international clinical trials. Thirty companies (68% of the French market) have participated in this 6(th) survey which involved 79 countries, a greater number of Phases I/II, II and III studies (420 versus 352 in 2010), a relatively stable number of included patients (246,895 versus 249,704 in 2010) and a greater number of centers (32,965 versus 24,337 in 2010). ⋯ France ranks at an average position among European countries in regards to quantitative and qualitative data, and its state-of-art in early stages is still recognized. Its good performance in oncology and orphan diseases are major assets of competitiveness.
-
Letter Case Reports
[Accidental poisoning with transdermal fentanyl patch in a 8 months old infant].
-
Letter Case Reports
Late and severe acute necrotizing pancreatitis in a patient with liraglutide.
-
Letter Case Reports
Effect of carbamazepine on fluindione's anticoagulant activity: a case report.
-
To assess the knowledge of physicians about generic drugs and their prescribing habits, with a view to making proposals for developing the use of generic drug in Morocco. ⋯ In order to increase the use of generic drugs, better information for physicians is necessary. Other ways can be implemented, first establish the quality of Moroccan generic by bioequivalence studies and think about steps to put in place to encourage doctors and pharmacists to prescribe and dispense generic drugs, particularly the rights of substitution.